Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-919373 DDI with Rosuvastatin and Atorvastatin
NCT02089061Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2014
- Primary completion
- May 2014
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of BMS-919373 in Atrial fibrillation (AFib) and acute coronary syndrome (ACS) (2 cohorts), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration, Area under the plasma concentration-time curve from time zero to 72 hours and 2 more. Started Mar 2014; status: completed.
02
Drugs
BMS-919373
03
Conditions
Atrial fibrillation (AFib)acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT02089061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02089061.